md-medicaldata

Authors

 

Nada Kuljić-Kapulica, Beograd, Danijela Djurić-Petković
Institut za mikrobiologiju, Vojnomedicinska akademija, Beograd

 

• The paper was received on 14.11.2015. / Accepted on 20.11.2015.

 

Abstract

 

Ebola virus causes a severe and often deadly hemorrhagic fever. Mortality rates for disease range from 25 percent to 90 percent. Ebola iz considered an emerging infectious disease. Epidemics of Ebola virus have occurred mainly in African countries.
The Ebola virus gained widespread attention in the 2014 when an outbreak in West Africa became the largest filovirus outbreak reported in history.

 

 

References

 

1. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res 1995; 39:129-50.
2. Peters CJ, Khan AS. Filovirus disesases. Curr Top Microbiol Immunol 1999; 235:85-95.
3. Kuhn JH, Becker S, Ebihara H et al. Proposal for a revised taxonomy of the family Filoviridae: classification, namex of taxa and viruses, and virus abbreviations. Arch Virol 2010;155:2083-103.
4. Bowen ETW, Lloyd G, Harris WJ et al. Viral haemorrhagic  fever in southern Sudan and northern Zaire. Preliminary studies on the aetiologicaal agent. Lancet 1977; 1:571-573.
5. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849-62.
6. Cenciarelli O, Gabbarini V, Pietropaoli S, Malizia A, Tamburrini A et al. Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013-2015. Virus Research 2015; 210; 318-326.
7. Kuljić-Kapulica Nada. Virusi kao biološko oružje. U:  Biološko oružje, Vojnoizdavački zavod 2003. Beograd.
8. Baize S, Pannetier D, Oestereich L et al. Emergence of Zaire Ebola virus in Guinea. N Engl J Med 2014;371:1418-25.
9. A.Mirazimi.  Ebola virus disease: societal challenges and new treatments. J of Internal Medicine 2015;278(10): 227-237.
10. Team Whder, Aqua-Agum J, Ariyarajah A, Aylward B et al. West African Ebola epidemic after one year-showing butnot jet under control. N Engl J Med 2015; 372:584-7.
11. 11.WHO.http://whoint/csr/disease/ebola/situation-reports/en/.WHO.2015
12. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011;204:S8 10-16.
13. William B.Millard. Channeling, high-level biocontainment and research. Annals of Emergency Medicine 2015; 65(2):A15-A22.
14. M. Goeijenbier et al. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med 2014; 72(9):442-8.
15. 15.Wedmann M, Muhlberger E, Hufert FT. Rapid detection protocol for filiviriruses. J Clin Virol 2004; 30(1): 94-9.
16. Mupapa K, Massamba M, Kibadi K et al. Treatment of Ebola hemorrhagic fever with blood transfusions from covalescent patients. International Scienttific and Technical Committee. J Infect Dis 1999;179:S18-S23.
17. Qiu X, Wang G, Andet J et al. Reversion of advanced Ebola virus disease in nonhuman primates with Zmapp. Nature 2014;514(7520):47-53.
18. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral. Res. 2013;100:446-54.
19. 19.Hague A, Hober D, Blondaux S. Addressing therapeutic option for Ebola virus infection in current and future outbreaks. 2015; 59(10): 5892-5902.
20. Marz A, Feldmann H, Geibert TW, Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Bidef 2011; S1(4).
21. Angela Huttner, Julie-Anne Dayer, Sabine Yerly, Christophe Combescure, Floriane Anderset, Jules Desmeules et.al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase ½ trial.  The Lancet Infectious Diseases 2015; 15: 1156-1166.
22. Stanley DA et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Med 2014; 20, 1126-1129.
23. Giovani Rezza. A vaccine against Ebola: problems and opportunities. Human vaccines&Immunotherapeutics 2015; 11(5):1258-1260.
24. Ye L, Yong C. Development of vaccine for prevention of Ebola virus infection. Microbes Infect 2015; 17(2): 98-108.
25. Henao-Restrepo AM, Longini IM, Egger M,Dean NE, Edmunds WJ, Camacho MW, et al. Efficancy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386(9996):857-66.

PDF Kuljić Kapuljica N and Đurić Petković D. • MD-Medical Data 2015;7(4): 301-305